Upgrade to SI Premium - Free Trial

Truist Securities on Viridian Therapeutic (VRDN): data places SC Ele' as 'notable therapeutic companion' to IV Veli'

March 30, 2026 8:46 AM
Truist Securities analyst Greg Renza reiterated a Buy rating and $40.00 price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments